Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell vaccine + imiquimod
- Development stage
- Unknown
- Lead developer
- Medical University of Vienna
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Oral, Systemic, Topical
01
Overview
A combination immunotherapy approach using dendritic cell vaccines with imiquimod, a TLR7/8 agonist. Dendritic cells are loaded with tumor antigens and administered as a vaccine, while imiquimod enhances immune responses by stimulating plasmacytoid dendritic cells to produce type I interferons, promoting T-cell priming, and creating a favorable immune environment.
02
Targets
TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on dendritic cell vaccine + imiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell vaccine + imiquimod.